News Veru Inc.

Equities

VERU

US92536C1036

Real-time Estimate Cboe BZX Other stock markets 09:55:19 2024-05-23 am EDT			5-day change	1st Jan Change
1.32 ^USD	-3.65%		-2.92%	+84.72%

May. 14	B. Riley Securities Starts Very With Buy Rating, $5 Price Target	MT
May. 08	Earnings Flash (VERU) VERU Posts Q2 Revenue $4.1M	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Veru to Present at the Jefferies Global Healthcare Conference	May. 22	AQ
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss	May. 15	AQ
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week	May. 14	AQ
B. Riley Securities Starts Very With Buy Rating, $5 Price Target	May. 14	MT
Earnings Flash (VERU) VERU Posts Q2 Revenue $4.1M	May. 08	MT
Transcript : Veru Inc., Q2 2024 Earnings Call, May 08, 2024	May. 08
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program	May. 08	AQ
HC Wainwright Adjusts Veru Price Target to $3 From $2, Maintains Buy Rating	May. 06	MT
Veru to Present at the GLP-1 Based Therapeutics Summit	May. 02	AQ
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024	May. 01	AQ
Veru : Corporate Presentation, May 2024	Apr. 30	PU
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss	Apr. 30	AQ
Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss	Apr. 30	CI
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11	Apr. 25	AQ
Oppenheimer Cuts Veru Price Target to $5 From $7, Maintains Outperform Rating	Apr. 15	MT
Veru Announces Date of 2024 Annual Meeting of Shareholders	Apr. 01	AQ
Veru Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Apr. 01	CI
Raymond James Starts Very With Outperform Rating, $3 Price Target	Mar. 28	MT
Veru Reschedules Annual Meeting of Shareholders	Mar. 25	AQ
Veru Reschedules Annual Meeting of Shareholders	Mar. 22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Veru Inc.

Equities

VERU

US92536C1036

Summary

Filters